Company Now Has 17 Products Registered and Approved With The Ministry
DENVER, CO / ACCESSWIRE / December 14, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the ''Company'' or
''United Cannabis'') today announced that Jamaica's Ministry of Health has approved its patent-protected Prana Medicinal
Sublinguals and Prana Medicinal Transdermals for use by registered medicinal cannabis patients.
The Prana Collection is the foundation of the Company's cannabis-centric formulations, which patients have found effective in
providing relief from the symptoms of arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle
recovery, migraines, and various skin conditions.
The products will be manufactured and distributed by the Company's Jamaican subsidiary, Cannabinoid Research & Development
Limited (''CRD''). CRD is currently making preparations to produce the complete line of Prana products in Jamaica in anticipation
of receiving a license from the Cannabis Licensing Authority.
Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement, ''Jamaica remains at the forefront
of the medical cannabis market, both domestically and as a distribution hub for other markets around the world, including Canada,
the European Union and Australia. Our partners at CRD are working to establish relationships with potential distributors in those
markets so that we're ready to initiate sales as soon as we are licensed to begin production.''
About Cannabinoid Research & Development Limited
Cannabinoid Research & Development (CRD), a subsidiary of United Cannabis, is a Jamaican based corporation pursuing local
licensing to advance the use of medical cannabis therapies through biomedical research and development for the nutraceutical
industry. CRD focuses on genetic restoration, cannabinoid isolation techniques, scientific research, educational programs, and
promotes domestic job opportunities. John Sayers, along with Kenyama Brown, local Jamaican directors and executives of CRD, coupled
with Jamaican partners specializing in agricultural science and plant based medicine, will help United Cannabis implement Sayer's
40 years of agricultural methodologies into localized educational curriculums, job training programs, and help with integration of
localized products.
About United Cannabis Corporation
United Cannabis Corporation is a biotechnology company dedicated to the development of phyto-therapeutic based products
supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the
application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the
quality of life for patients around the world. Most of the Company's products are patent protected first in class medicines with
applications to a global market. United Cannabis trades on the OTCQB under the symbol CNAB.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the
Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors
created by those rules. All statements, other than statements of fact, included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could
differ materially from those anticipated in such statements. Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation
